Chemokine receptors, or CCRs, are cytokine receptors that can be found on the surface of some cells and interact with specific chemokines. Mammals have 19 different chemokine receptors that have been identified. They are all members of a large protein family known as G protein-coupled receptors because they each have a 7-transmembrane (7TM) structure and couple to G-protein for signal transduction inside of a cell. Chemokine receptors cause an increase in intracellular calcium (Ca2+) ions after interacting with their particular chemokine ligands (calcium signaling).Cell responses result from this, and one of them is the beginning of the chemotaxis process, which directs the cell to the desired area of the organism. The four different subfamilies of chemokines that chemokine receptors bind are grouped into four families: CXC chemokine receptors, CC chemokine receptors, CX3C chemokine receptors, and XC chemokine receptors. Some chemokine receptors act as entry points for HIV, while others support inflammatory conditions and cancer.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V51092 | CCR6 inhibitor 1 | 2437547-04-9 | CCR6 Inhibitor 1 is a potent and potent example of CCR6 with IC50s of 0.45 and 6 nM for monkey and human CCR6, respectively, which is a close match for human CCR1 (IC50, >30000 nM) and CCR7 (IC50), 9400 nM). |
|
V4831 | CCR8 antagonist 1 | 723304-76-5 | CCR8 antagonist 1 (compound 15) is a potent human CCR8 antagonist (inhibitor) with Ki of 1.6 nM. |
|
V3746 | Cenicriviroc | 497223-25-3 | Cenicriviroc (formerly known as TAK-652 or TBR-652) is a novel, orally bioactive, and dual antagonist of CCR2/CCR5, it also inhibits both HIV-1 and HIV-2, and has the potential for the treatment of HIV infection. |
|
V3747 | Cenicriviroc Mesylate | 497223-28-6 | Cenicriviroc Mesylate (formerly known as TAK-652 Mesylate or TBR-652 Mesylate) is a novel, orally bioactive, and dual antagonist of CCR2/CCR5, it also inhibits both HIV-1 and HIV-2, and has the potential for the treatment of HIV infection. |
|
V51110 | CKLF1-C19 | 960358-79-6 | CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). |
|
V74753 | CMPD167 (MRK-1) | 313994-79-5 | CMPD167 (MRK-1) is an orally bioactive CCR5 inhibitor (antagonist) with potent anti-viral effect in vitro. |
|
V3603 | GSK2239633A | 1240516-71-5 | GSK2239633A (GSK-2239633A), a 4-aminoindazole sulfonamide, is a novel and potent antagonist of human CC-chemokine receptor 4 (CCR4) with anti-inflammatory activity. |
|
V4079 | INCB3344 | 1262238-11-8 | INCB3344 (INCB-3344) is a novel, potent, selective,orally bioavailable small molecule antagonist of the CCR2 receptor with anti-inflammatory activity. |
|
V76893 | INCB3344 R-isomer | INCB3344 R-isomer is the R-isomer of INCB3344. | |
|
V74751 | IPG7236 | 2756350-91-9 | IPG7236 is a selective CCR8 antagonist. |
|
V51093 | Lazucirnon (ALK-4290; AKST-4290) | 1251528-23-0 | CCR3 inhibitor |
|
V51090 | Leronlimab (PRO-140) | 674782-26-4 | Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody (mAb). |
|
V51114 | Maraviroc-d6 | 1033699-22-7 | Maraviroc-d6 is the deuterium labelled form of Maraviroc. |
|
V51103 | Met-RANTES (human) | 1883816-50-9 | Met-RANTES (human) is part of a family of CCR5 antagonists. |
|
V4298 | MK0812 | 624733-88-6 | MK-0812 (MK0812) is a novel, potent and selective small molecule CCR2 antagonist with potential anti-Inflammatory and immunomodulatory activity. |
|
V4297 | MK0812 Succinate | 851916-42-2 | MK0812 Succinate (MK-0812) is a novel, potent and selective small molecule CCR2 antagonist with anti-Inflammatory and immunomodulatory activity. |
|
V51100 | Mogamulizumab (KW-0761) | 1159266-37-1 | Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (mAb). |
|
V51091 | PF-07054894 | 2413693-96-4 | PF-07054894 is a potent CCR6 antagonist. |
|
V3261 | PF-4136309 (INCB-8761) | 1341224-83-6 | PF-4136309 (formerly known as INCB8761) is a novel, potent, selective, and orally bioavailable small molecule CCR2 antagonist with IC50 values of 5.2 nM, 17 nM and 13 nM for human, mouse and rat CCR2, respectively. |
|
V51101 | Plozalizumab | 1610761-46-0 | Plozalizumab (MLN-1202) is a specific humanized anti-CCR2 antibody. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
